Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 7Withdrawn 1Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 64Breast 28Sarcoma 15Other hematologic neoplasm 15Gynecologic 11Genitourinary 9Plasma cell 6Gastrointestinal 6CNS 6Thoracic 2Other solid neoplasm 2Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 18Specimen Handling 9Magnetic Resonance Spectroscopy 9Bevacizumab 8Biopsy 7Paclitaxel 6Nivolumab 6atezolizumab 5Cyclophosphamide 5Surveys and Questionnaires 4Standard of Care 4Practice Guidelines as Topic 4Oxaliplatin 4Ipilimumab 4osimertinib 3niraparib 3durvalumab 3cemiplimab 3avelumab 3X-Rays 3Radiotherapy 3Radiosurgery 3Radiation 3Pemetrexed 3Leucovorin 3Irinotecan 3Interviews as Topic 3Fluorouracil 3Carboplatin 3trastuzumab deruxtecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Doxorubicin × Tumor-Agnostic × Clear all
NCT03203525 2026-02-25

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
38 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡